stockportfolio.pro
TG Therapeutics, Inc. P/E Ratio 2011–2025
TG Therapeutics, Inc. (TGTX) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -18.5%/yr over 14 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 10.76 | -94.6% |
| FY 2024 | 200.67 | +5.7% |
| FY 2023 | 189.78 | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
Source: TG Therapeutics, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for TG Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeTG Therapeutics, Inc. — frequently asked questions
What is TG Therapeutics, Inc.'s price-to-earnings ratio?
TG Therapeutics, Inc. (TGTX) reported price-to-earnings ratio of 10.76 for fiscal year 2025, per its SEC filings.
How has TG Therapeutics, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2011 and 2025, TGTX's price-to-earnings ratio declined at roughly 18.5% per year (compound annual rate), from 189.78 to 10.76.
Where does this data come from?
Figures are computed from TG Therapeutics, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.